Multiple colon ulcerations, perforations and death during treatment of malignant melanoma with sorafenib;Multiple Kolonulzera mit Perforationen und Tod nach der Behandlung eines malignen Melanoms mit Sorafenib

Deutsche Medizinische Wochenschrift

Volumn 134, Issue , 2009, Pages 1464-1466

  Frieling, T ^a   Heise, J ^a   Wassilew, S W ^a  

^a HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

antiangiogenic multi kinase inhibitors; colonic perforation; colonic ulcera; malignant melanoma; Nexavar ; sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; SORAFENIB;

ACUTE ABDOMEN; AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; COLON DISEASE; COLON RESECTION; DIARRHEA; FATALITY; HUMAN; ILEOSTOMY; INTESTINE PERFORATION; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; PATHOLOGY; SKIN TUMOR; ULCER;

ABDOMEN, ACUTE; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; COLECTOMY; COLONIC DISEASES; DIARRHEA; FATAL OUTCOME; HUMANS; ILEOSTOMY; INTESTINAL PERFORATION; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; PROTEIN KINASE INHIBITORS; PYRIDINES; SKIN NEOPLASMS; ULCER;

EID: 67649939035     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1225301     Document Type: Article

References (7)

1. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25 (7): 884-896
2. Egberts F, Kähler KC, Livingstone E, Hauschild H. Metastatic Melanoma: Scientific Rationale for Sorafenib Treatment and Clinical Results. Onkologie 2008; 31: 398-403
3. Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23 (suppl): 1093s
4. Greil R, Micksche M. Sorafenib.In: Zielinski C, ed (Hrsg). Arzneimittel Profil. Medizin Medien Austria, 2006: 1-16
5. Pierce GF, Mustoe TA, Lingelbach J et al. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J Cell Biol 1989; 109: 429-440
6. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008; 61 (4): 535-548
7. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109